Today's Washington Post has an article on how the simple sandwich can affect the price of prescription drugs. Say what?
The article cites a study published in JAMA that surveyed 280,000 doctors and their prescriptions to Medicare patients. Doctors who received free meals of average value $20, were much more likely to prescribe drugs from the vendor paying for lunch:
For example, one of the promoted drugs was a brand-name statin, Crestor, used to lower cholesterol. Another treatment, Lipitor, has been shown to work as well as Crestor, and a cheap generic was available for Lipitor. Doctors who received a meal focused on Crestor four or more times prescribed it 1.8 times as frequently as doctors who received no meals....
JAMA Internal Medicine editor-at-large Robert Steinbrook wrote. "If drug and device manufacturers were to stop sending money to physicians for promotional speaking, meals, and other activities without clear medical justifications and invest more in independent bona fide research on safety, effectiveness, and affordability, our patients and the health care system would be better off."
But what does this have to do with CASBs? A lot as it turns out. When choosing a CASB, ask the vendor how many of its "customers" are "advisors" to the company with associated share grants. I know one CASB vendor who has about a hundred advisors, many of them also "customers." And another CASB that might not be far behind.
At Bitglass, we have zero overlap between our advisors and customers. Our product speaks for itself!